BRPI0507436A - conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados - Google Patents

conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados

Info

Publication number
BRPI0507436A
BRPI0507436A BRPI0507436-3A BRPI0507436A BRPI0507436A BR PI0507436 A BRPI0507436 A BR PI0507436A BR PI0507436 A BRPI0507436 A BR PI0507436A BR PI0507436 A BRPI0507436 A BR PI0507436A
Authority
BR
Brazil
Prior art keywords
chemically modified
human growth
modified human
growth hormone
receptor antagonist
Prior art date
Application number
BRPI0507436-3A
Other languages
English (en)
Inventor
Thomas J Girard
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0507436A publication Critical patent/BRPI0507436A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

CONJUGADOS ANTAGONISTAS DO RECEPTOR DO HORMÈNIO DO CRESCIMENTO HUMANO QUIMICAMENTE MODIFICADOS A presente invenção fornece antagonistas do receptor do hormónio do crescimento humano (hGH) quimicamente modificados preparados anexando um fração de polietileno glicol única ao N-terminal. A proteína quimicamente modificada de acordo com a presente invenção tem menor heterogeneidade de Peguilação e pode ter maior afinidade de ligação.
BRPI0507436-3A 2004-02-09 2005-01-31 conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados BRPI0507436A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54307804P 2004-02-09 2004-02-09
PCT/IB2005/000228 WO2005075021A2 (en) 2004-02-09 2005-01-31 Chemically-modified human growth hormone receptor antagonist conjugates

Publications (1)

Publication Number Publication Date
BRPI0507436A true BRPI0507436A (pt) 2007-07-03

Family

ID=34837575

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507436-3A BRPI0507436A (pt) 2004-02-09 2005-01-31 conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados

Country Status (7)

Country Link
US (1) US20090203589A1 (pt)
EP (1) EP1715895A2 (pt)
JP (1) JP2007522198A (pt)
BR (1) BRPI0507436A (pt)
CA (1) CA2553899A1 (pt)
MX (1) MXPA06007848A (pt)
WO (1) WO2005075021A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448512B (zh) * 2005-12-14 2015-11-25 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
EP2076245A2 (en) * 2006-09-15 2009-07-08 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
WO2013113074A1 (en) * 2012-02-03 2013-08-08 Antisense Therapeutics Ltd Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
KR102167827B1 (ko) 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
EP3983002A4 (en) 2019-06-17 2023-08-02 Molecular Technologies Laboratories LLC THERAPEUTIC PEGYLATED GROWTH HORMONE ANTAGONISTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000003I1 (de) * 1995-09-21 2006-05-04 Genentech Inc Varianten des Menschlichen Wachstumshormons
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
WO2004026251A2 (en) * 2002-09-20 2004-04-01 Pharmacia Corporation Process for decreasing aggregate levels of pegylated protein
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group

Also Published As

Publication number Publication date
JP2007522198A (ja) 2007-08-09
MXPA06007848A (es) 2006-09-04
CA2553899A1 (en) 2005-08-18
WO2005075021A3 (en) 2006-07-20
WO2005075021A2 (en) 2005-08-18
EP1715895A2 (en) 2006-11-02
US20090203589A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
RU2014122609A (ru) Модифицированная константная область антитела
EP1432433A4 (en) ANTAGONISTS
BRPI0507436A (pt) conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
NO20031179D0 (no) Chemokin-reseptorbindende heterocykliske forbindelser
HK1080511A1 (en) Il-1 receptor based antagonists and methods of making and using
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
DE60231868D1 (de) Folat-mimetika und deren folatrezeptorbindende konjugate
ATE516305T1 (de) Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
EP2279754A3 (en) Remodelling and glycoconjugation of human growth hormone (hGH)
EP2526968A3 (en) Nogo receptor antagonists
IS7677A (is) Mótlyf Nogo-viðtaka
WO2006043972A8 (en) Chimeric protein
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
BR122016022033B8 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
EP2316944A3 (en) Binding agents: chimeric ligand/receptor proteins
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
JO2859B1 (en) Peptides and compounds that are associated with a receptor
WO2005000877A3 (en) Novel melanocortin receptor templates, peptides, and use thereof
MEP48508A (en) Peptides and compounds that bind to thrombopoietin receptors
WO2006087163A3 (en) Novel in vitro methods for studying receptors recognizing volatile compounds
WO2001072771A3 (en) Insulin and igf-1 receptor agonists and antagonists
DE602004027039D1 (de) Cytokinpolypeptidvarianten
WO2003089582A3 (en) Multimeric ligands with enhanced stability
WO2004058189A3 (en) Chemokine antagonists and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/48 (2006.01), A61P 5/04 (2006.01)

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01), A61P 5/04 (2006.01)